Last updated: February 20, 2026
Qoliana (chloroprocaine hydrochloride) is a local anesthetic used in various medical procedures. Unlike large-scale blockbuster drugs, Qoliana's supply chain involves specialized manufacturers and distributors primarily based in North America and Europe.
Key Manufacturers of Qoliana
1. AbbVie (formerly part of Abbott Laboratories)
- Product Portfolio: Qoliana is marketed under the brand name Qoliana by AbbVie.
- Manufacturing: AbbVie holds manufacturing rights and supplies through its global production facilities.
- Availability: Primarily available through healthcare providers in North America and certain Asian markets.
2. Fresenius Kabi
- Product Portfolio: Produces generic chloroprocaine hydrochloride solutions comparable to Qoliana.
- Manufacturing: Operates multiple facilities in Europe, Asia, and North America.
- Market Access: Supplies to hospitals and clinics worldwide, sometimes under private labels.
3. Teva Pharmaceutical Industries
- Product Portfolio: Manufactures generic chloroprocaine products, often used as alternatives to Qoliana.
- Manufacturing: Facilities in Israel, India, and Europe.
- Market Access: Distributes through global wholesale and hospital channels.
4. Pfizer
- Product Portfolio: Historic manufacturer of similar local anesthetics, with some chloroprocaine formulations.
- Market Role: Provides supply in certain markets, though Qoliana-specific supply appears limited.
5. Local and Regional Generic Manufacturers
- Examples: Many small pharma companies in India, China, and Eastern Europe produce chloroprocaine-based products for regional markets.
- Supply Chain: Increasingly significant due to tightened regulations and the push for cost-effective generics.
Distribution Channels
- Authorized Distributors: Major hospitals and clinics procure Qoliana through authorized medical supply distributors such as McKesson, Cardinal Health, and Henry Schein.
- Regional Suppliers: Smaller distributors often supply generic chloroprocaine solutions in emerging markets.
- Pharmaceutical Wholesalers: Larger wholesalers typically stock both brand-name Qoliana and generic equivalents, with supply contracts often negotiated directly with manufacturers.
Market Dynamics
- Patent Expiry: Qoliana's patent protection has expired or is nearing expiration, increasing generic competition.
- Pricing Trends: Generic producers have driven prices down, expanding access but creating a more fragmented supply chain.
- Regulatory Approvals: Regulatory agencies like the FDA, EMA, and local authorities have approved multiple chloroprocaine formulations, facilitating broad distribution.
Summary Table: Key Suppliers and Sources
| Supplier |
Product Type |
Manufacturing Location |
Market Coverage |
Notes |
| AbbVie |
Brand Qoliana |
North America, Europe |
North America, select Asia |
Exclusive rights, primary manufacturer |
| Fresenius Kabi |
Generic chloroprocaine |
Europe, Asia, NA |
Global |
Widely used generic alternative |
| Teva |
Generic chloroprocaine |
Israel, India, Europe |
Global |
Large scale generic producer |
| Pfizer |
Generic local anesthetics |
Global |
Limited to some markets |
Historically involved in local anesthetics |
| Regional manufacturers |
Various generics |
Asia, Europe, Africa |
Local and emerging markets |
Increasing presence due to cost advantages |
Key Takeaways
- The primary manufacturer of Qoliana is AbbVie, with generic chloroprocaine options supplied by companies such as Fresenius Kabi and Teva.
- Supply chains rely on authorized distributors and wholesalers, with regional small-scale producers increasing availability.
- Patent expiration has led to increased generic competition, affecting market prices and access.
- Procurement depends heavily on local regulatory approvals, hospital tenders, and distribution agreements.
FAQs
1. Is Qoliana available globally?
Availability varies by region. North America primarily sources from AbbVie, while generic options are available in Europe, Asia, and other regions through various local manufacturers.
2. Who are the main suppliers of generic chloroprocaine?
Fresenius Kabi and Teva are the leading global producers of generic chloroprocaine formulations used as alternatives to Qoliana.
3. Can hospitals procure Qoliana directly from manufacturers?
Typically, hospitals obtain Qoliana through authorized distributors or large pharmacy chains, not directly from manufacturers.
4. Are there regulatory differences affecting supplier access?
Yes. Regulatory approvals by agencies like the FDA or EMA influence market access. Generic manufacturers must meet local standards to sell chloroprocaine products.
5. How does patent expiry influence supplier competition?
Patent expiry allows generic manufacturers to produce chloroprocaine formulations, increasing supplier options and reducing prices.
References
[1] U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency. (2023). Summary of Product Characteristics for Chloroprocaine.
[3] GlobalData Healthcare. (2022). Market Analysis of Local Anesthetics.
[4] IMS Health. (2022). Pharmaceutical Distribution Data.
[5] PharmaBoardroom. (2021). The Generics Market in Emerging Economies.
